Glenmark Pharmaceuticals (GPL), has unveiled its Strategic Blueprint to transition into an Innovation?led Global Pharmaceutical Organization over the next decade. The Blueprint conveys the company’s greater business alignment expanding generics to prioritizing research and development efforts in three key therapeutic areas: oncology, respiratory and dermatology.
The innovative oncology pipeline, with candidates targeting multiple tumors, is the top priority with the greater promise to deliver novel, first?in?class molecules and help company evolve into a fully commercialized, innovation?led pharmaceutical company. The strategic blueprint also outlines aggressive plans to increase company’s presence worldwide by strengthening focus on complex generics including injectables, expanding its manufacturing footprint (growing from two formulation facilities to 17).
Glenmark’s current portfolio consists of 109 products authorized for distribution in the US marketplace and 62 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1770.55 |
Dr. Reddys Lab | 1200.30 |
Cipla | 1480.20 |
Lupin | 2046.40 |
Zydus Lifesciences | 941.40 |
View more.. |